Scientific Advisory Board Member Resigns Due to Conflict with Responsibilities with Important Public Sector Entity
Enochian BioSciences (NASDAQ: ENOB) announced the resignation of Dr. Peter Piot as Chairperson of the Respiratory Diseases Scientific Advisory Board due to his advisory role with a major governmental organization on COVID-19. Dr. Piot expressed his continued admiration for Enochian's innovative science and pipeline potential but cited a conflict of interest as the reason for his departure. Enochian BioSciences focuses on gene-modified therapies for infectious diseases and cancer, with applications for various conditions including HIV/AIDS and Influenza.
- Retains Dr. Piot's confidence in Enochian's innovative science and pipeline.
- Loss of experienced leadership from the scientific advisory board.
- Potential impact on strategic direction and advice due to advisory responsibilities of Dr. Piot.
LOS ANGELES, Oct. 15, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, announced that Dr. Peter Piot has resigned as Chairperson of the Respiratory Diseases Scientific Advisory Board due to important responsibilities advising a major governmental organization on COVID-19 that creates a conflict.
“I remain very impressed by, and enthusiastic about, the innovative science and potential of Enochian BioSciences’ entire pipeline,” said Dr. Piot. “However, my responsibilities advising a governmental organization do not allow me to continue as a scientific advisor.”
About Enochian BioSciences, Inc.
Enochian BioSciences, Inc. is a biopharmaceutical company focused on developing innovative platforms for gene-modified cellular and immune therapies to potentially cure and treat deadly diseases. The company’s gene-modified cell and immune therapy platforms can potentially be applied to multiple indications, including HIV/AIDS, Hepatitis B, all Corona and Influenza viruses, and Oncology. For more information, please visit Enochianbio.com
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Enochian BioSciences’ most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Enochian BioSciences undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
FAQ
Why did Dr. Peter Piot resign from Enochian BioSciences?
What impact does Dr. Piot's resignation have on Enochian BioSciences?
What is Enochian BioSciences focused on developing?
What indications can Enochian's therapies potentially address?
